The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...
Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology ...
This important manuscript provides insights into the competition between Splicing Factor 1 (SF1) and Quaking (QKI) for binding at the ACUAA branch point sequence in a model intron, regulating exon ...
Researchers unveil the inner mechanisms of the most intricate and complex molecular machine in human biology. Scientists at the Centre (CRG) in Barcelona have developed the first comprehensive ...
US FDA grants rare paediatric designation to ARTHEx Biotech’s ATX-01 for the treatment of myotonic dystrophy type 1: Valencia, Spain Friday, November 8, 2024, 16:00 Hrs [IST] AR ...
LDLR, which utilizes first in class mRNA upregulation and APOB ... between slower rates of caudate atrophy predicting ...
Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh Chivukula ...
To amplify mRNA, our therapeutic ASO drug candidates target regulatory ... associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback